Clinical trials
Phase 1 Breast Neoplasms trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
96 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 6 |
| 2013 | 10 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 10 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 9 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 53 |
| Active, not recruiting | 14 |
| Recruiting | 13 |
| Terminated | 13 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 19 |
| Eli Lilly and Company | 9 |
| SOLTI Breast Cancer Research Group | 7 |
| Hoffmann-La Roche | 6 |
| AbbVie | 5 |
| Genentech, Inc. | 5 |
| AstraZeneca | 3 |
| Centro Nacional de Investigaciones Oncologicas CARLOS III | 3 |
| GlaxoSmithKline | 3 |
| Daiichi Sankyo | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 96 |
| Neoplasms | 21 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Ovarian Neoplasms | 13 |
| Colorectal Neoplasms | 12 |
| Neoplasm Metastasis | 12 |
| Stomach Neoplasms | 11 |
| Endometrial Neoplasms | 10 |
| Lung Neoplasms | 9 |
| Colonic Neoplasms | 7 |
Trials
Showing 1 to 25 of 96. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.